Astra Zeneca faces potential multimillion-dollar fines in China
Astra Zeneca could be forced to pay up up to $8 million in fines for allegedly unpaid import duties in China, as the company seeks to rebuild trust following earlier controversies.
Despite Astra Zeneca having several promising drugs in development, the company is facing challenges in its two largest markets – the United States and China. In China, operations are being affected by past controversies, as previously reported by Life Science Sweden, while in the U.S., the business is under threat from potential tariffs on pharmac...
Vill du få åtkomst till allt?
Prova 30 dagar för 0 kr.
Inga bindningstider eller kortuppgifter krävs.
Prova nu
Köp en prenumeration
Utforska våra prenumerationslösningar och välj den som passar dina behov.
Välj din prenumeration